World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 19 February 2015
Main ID:  NCT00054938
Date of registration: 13/02/2003
Prospective Registration: Yes
Primary sponsor: Brigham and Women's Hospital
Public title: Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)
Scientific title: A Randomized Controlled Trial of Strategies for the Prevention of Accelerated Atherosclerosis in Systemic Lupus Erythematosus - A Pilot Study
Date of first enrolment: March 2003
Target sample size: 150
Recruitment status: Completed
URL:  http://clinicaltrials.gov/show/NCT00054938
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment  
Phase:  Phase 2
Countries of recruitment
United States
Contacts
Name:     Matthew H. Liang, MD, MPH
Address: 
Telephone:
Email:
Affiliation:  Brigham and Women's Hospital
Key inclusion & exclusion criteria

Inclusion Criteria

- SLE as defined by the 1997 American College of Rheumatology criteria

- Acceptable methods of contraception

Exclusion Criteria

- Participation in another experimental protocol for ASVD prevention

- Heavy alcohol consumption ( >= 3 drinks/day)

- Aspirin intolerance

- Certain medications, including coumadin, ACE inhibitors, potassium supplements,
potassium sparing diuretics, cyclosporine, and lithium

- Peptic ulcer disease within 6 months prior to study entry

- History of an intracranial bleed or brain tumor

- Bleeding diathesis

- History of allergy or sensitivity to ACE inhibitors

- Uncontrolled high blood pressure (180 mm Hg/110 mm Hg)

- Creatinine > 2.0 mg/dl

- Renal artery stenosis

- Pregnant or breastfeeding

- Abnormal liver function tests (ALT > 2 X upper limit of normal)

- History of a muscle disease, or baseline CPK > 500U/L or 2 X upper limit of normal



Age minimum: 18 Years
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Lupus
Systemic Lupus Erythematosus
Intervention(s)
Drug: Vitamins: B6, B12, and folate
Behavioral: heart health educational program
Drug: aspirin
Drug: ramipril
Drug: pravastatin
Primary Outcome(s)
Secondary Outcome(s)
Secondary ID(s)
P60 AR47782 NIAMS-077
P60AR047782
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history